menu
    • menu
    [{"orgOrder":0,"company":"Qunol","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sanofi to Acquire Qunol\u00ae, a Fast-Growing U.S. Brand in the Healthy Aging Segment","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Acquisition","leadProduct":"Coenzyme Q10","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Qunol","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Qunol \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Qunol \/ Sa.."},{"orgOrder":0,"company":"Qunol","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sanofi Completes Acquisition of Qunol\u00ae","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Acquisition","leadProduct":"Coenzyme Q10","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Qunol","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Qunol \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Qunol \/ Sa.."},{"orgOrder":0,"company":"Lipocine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Testosterone Undecanoate","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Lipocine","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Hormone","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lipocine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/.."}]

    Find Clinical Drug Pipeline Developments & Deals for (+-)-alpha-Tocopherol

    Menu

    (+-)-alpha-Tocopherol

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Lipocine

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed

                            Lipocine

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Testosterone Undecanoate,Vitamin E

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with ...

                            Details : LPCN 2401, an oral proprietary combination of anabolic androgen receptor agonist (Testosterone Undecanoate) and α-tocopherol, an antioxidant, is being investigated for the treament of obesity.

                            Brand Name : LPCN 2401

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 11, 2024

                            Lead Product(s) : Testosterone Undecanoate,Vitamin E

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Qunol

                            Country arrow
                            Formnext Forum
                            Not Confirmed

                            Qunol

                            Country arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Coenzyme Q10,Vitamin E

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Sponsor : Sanofi

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Sanofi Completes Acquisition of Qunol®

                            Details : Through the acquisition, addition of Qunol’s CoQ10 (ubiquinone) and Turmeric products strengthens Sanofi’s CHC Vitamin, Mineral and Supplements category, one of the largest and fastest-growing consumer health categories in the US.

                            Brand Name : Qunol CoQ10

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 29, 2023

                            Lead Product(s) : Coenzyme Q10,Vitamin E

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Sponsor : Sanofi

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Qunol

                            Country arrow
                            Formnext Forum
                            Not Confirmed

                            Qunol

                            Country arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Coenzyme Q10,Vitamin E

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Sponsor : Sanofi

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Sanofi to Acquire Qunol®, a Fast-Growing U.S. Brand in the Healthy Aging Segment

                            Details : Through the acquisition, addition of Qunol’s CoQ10 (ubiquinone) and Turmeric products strengthens Sanofi’s CHC Vitamin, Mineral and Supplements category, one of the largest and fastest-growing consumer health categories in the U.S.

                            Brand Name : Qunol CoQ10

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 27, 2023

                            Lead Product(s) : Coenzyme Q10,Vitamin E

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Sponsor : Sanofi

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth